Back to top
more

Annovis Bio (ANVS)

(Delayed Data from NYSE)

$6.65 USD

6.65
330,507

-0.64 (-8.78%)

Updated May 28, 2024 04:00 PM ET

After-Market: $6.91 +0.26 (3.91%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

by Zacks Equity Research

Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.

Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data

by Zacks Equity Research

Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

by Zacks Equity Research

Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.

Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M

by Zacks Equity Research

Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

by Zacks Equity Research

Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.

Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why

by Zacks Equity Research

Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.

Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

by Zacks Equity Research

Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.

PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

by Zacks Equity Research

Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.

Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control

by Zacks Equity Research

Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

by Zacks Equity Research

Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.

Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.

Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals

by Zacks Equity Research

Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

by Zacks Equity Research

Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.

Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues

by Zacks Equity Research

Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.

Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues

by Zacks Equity Research

Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.

Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.

Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises

by Zacks Equity Research

Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.

Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.

Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.